Testing COVID-19 medications using novel drug delivery technology for the eyes
b'
What if eye drops and injections used to treat eye diseases could be made to last longer in the eye, improving patient outcomes and reducing visits to the doctor? What if this drug delivery method could be applied to the lung, potentially improving outcomes for COVID-19 patients?
\\nIn Episode 8, hear how McMaster engineers at the Sheardown Lab are doing just that.
\\nGuests:
\\nHeather Sheardown, a professor in Chemical Engineering and Tier 1 Canada Research Chair in Opthalmic Biomaterials
\\nFran Lasowski, the executive director for the C20/20 Innovation Hub and PhD graduate in Chemical Engineering
\\n